Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Constantine Tam, Chan Cheah, John Seymour, Ricardo Parrondo, Mazyar Shadman, Damien Roos Weil, Stephan Stilgenbauer, Barbara Eichhorst, Herbert Eradat, Steven Treon, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Motohisa Takai, Amit Agarwal, Annamaria Frustaci

Blood (2025) 146 (Supplement 1): 3583.

https://doi.org/10.1182/blood-2025-3583

Published: 2025

Journal Articles

CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies

Chan Cheah, Mohamed Shanavas, Julio Chavez, Yanhong Tong, Xiaoyun (Nicole) Li, Prasanna Kumar, Amit Agarwal, Mary Ann Anderson, Nitin Jain

Blood (2025) 146 (Supplement 1): 1839.

https://doi.org/10.1182/blood-2025-1839

Published: 2025

Journal Articles

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Hang Quach, Rakesh Popat, Wenming Chen, Mary Kwok, Andrew Yee, Zhongxing Jiang, Flávia Xavier, Natalie Callander, Man Yuk Ho, Susan Bal, Michael Low, Douglas Sborov, Gabriel Man, Huan Cheng, Adam Idoine, Xin Wang, Amit Agarwal, Binod Dhakal

Blood (2025) 146 (Supplement 1): 102.

https://doi.org/10.1182/blood-2025-102

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Blood (2025) 146 (Supplement 1): 85.

https://doi.org/10.1182/blood-2025-85

Published: 2025

Journal Articles

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Meghan Thompson, Annamaria Frustaci, John Seymour, John Allan, Paolo Ghia, Olivier Dumas, Franck Morschhauser, Martin Dreyling, Stephan Stilgenbauer, Inhye Ahn, Romain Guieze, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Daniel Persky, Amit Agarwal, Carlo Visco

Blood (2025) 146 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2025-3895

Published: 2025

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study

John F. Seymour, Constantine S. Tam, Chan Y. Cheah, Ricardo D. Parrondo, John N. Allan, Judith Trotman, Ranjana H. Advani, Herbert A. Eradat, Pier Luigi Zinzani, Masa Lasica, Steven P. Treon, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, Anna Maria Frustaci

Blood (2024) 144 (Supplement 1): 860.

https://doi.org/10.1182/blood-2024-199212

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Meghan C. Thompson, Ricardo D. Parrondo, Anna Maria Frustaci, John N. Allan, Paolo Ghia, Irina Mocanu, Constantine S. Tam, Judith Trotman, Inhye E. Ahn, Stephan Stilgenbauer, Lydia Scarfo, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, John F. Seymour

Blood (2024) 144 (Supplement 1): 885.

https://doi.org/10.1182/blood-2024-199116

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study

Constantine S. Tam, Anna Maria Frustaci, Fontanet Bijou, Pier Luigi Zinzani, John F. Seymour, Masa Lasica, Herbert A. Eradat, Victor T.G. Lin, Maan Alwan, Irina Mocanu, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, Chan Y. Cheah

Blood (2024) 144 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2024-199154

Published: 2024

Journal Articles

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Blood (2023) 142 (Supplement 1): 1717.

https://doi.org/10.1182/blood-2023-188545

Published: 2023

Journal Articles

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

John F. Seymour, Chan Yoon Cheah, Ricardo Parrondo, Meghan C. Thompson, Don A. Stevens, Masa Lasica, Michael L. Wang, Abhijeet Kumar, Judith Trotman, Maan Alwan, Wei Ding, Kunthel By, Bilal Tariq, Xiangmei Chen, Shannon Fabre, Jason Paik, Amit Agarwal, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 4401.

https://doi.org/10.1182/blood-2023-180109

Published: 2023

Journal Articles

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Hang Quach, Doug Sborov, Dickran Kazandjian, Andrew Spencer, Michael Low, Susan Bal, Natalie S. Callander, Huan Cheng, Sheel Patel, Rocco J. Crescenzo, Amit Agarwal, Binod Dhakal

Blood (2023) 142 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2023-178735

Published: 2023

Journal Articles

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Nicholas Stong, María Ortiz-Estévez, Fadi Towfic, Mehmet Samur, Amit Agarwal, Jill Corre, Erin Flynt, Nikhil Munshi, Hervé Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (13): 1574–1583.

https://doi.org/10.1182/blood.2022016212

Published: 2023

Includes: Supplemental data

Journal Articles

Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

Nina Shah, Nikhil C. Munshi, Jesús G. Berdeja, Sundar Jagannath, Olivia Finney, Nathan Martin, Amit Agarwal, Everton Rowe, Timothy B. Campbell, Jesús F. San-Miguel

Blood (2021) 138 (Supplement 1): 1739.

https://doi.org/10.1182/blood-2021-148375

Published: 2021

Journal Articles

Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM

Noopur S. Raje, MD, Omar Nadeem, MD, Joseph Mikhael, MD FRCPC, MD, Catherine Ludwig, MB BChir, Amit Agarwal, MD PhD, Judith Inumerable, PGC, Teng J. Ong, MD, Sundar Jagannath, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141591

Published: 2020

Journal Articles

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD FRCPC, Christopher S. Seet, MD PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz, III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD PhD, Nizar J. Bahlis, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134189

Published: 2020

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

Noopur S. Raje, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Sagar Lonial, MD FACP, Nikhil C. Munshi, MD, Philippe Moreau, MD, Hartmut Goldschmidt, MD, Michele Cavo, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Liping Huang, PhD, Amit Agarwal, MD PhD, Julie Wang, PharmD, PhD, Timothy B. Campbell, MD PhD, Jesus F. San-Miguel, MD PhD, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-134319

Published: 2020

Journal Articles

Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma

Ankit Kansagra, MD, Yi Lin, MD PhD, Jesus G. Berdeja, MD, Nina Shah, MD, Albert Oriol, MD, Ibrahim Yakoub-Agha, Hermann Einsele, MD, Alessandro Rambaldi, MD, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Julie Wang, PharmD, PhD, Amit Agarwal, MD PhD, Timothy B. Campbell, MD PhD, Sagar Lonial, MD FACP

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134383

Published: 2020

Journal Articles

Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

Julie Rytlewski, PhD, Deepu Madduri, MD, Jaymes Fuller, PhD, Timothy B. Campbell, MD PhD, Afshin Mashadi-Hossein, MSc, Ethan G. Thompson, PhD, Yue Jiang, PhD, Nathan Martin, PhD, Dipen Sangurdekar, PhD, Olivia Finney, PhD, Hans Bitter, PhD, Amit Agarwal, MD PhD, Shari Kaiser, PhD, Kristen Hege, MD, Ronald J. Hause, Jr., PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134369

Published: 2020

Journal Articles

Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect ® MM Registry

Hans C. Lee, MD, Sikander Ailawadhi, MD, Cristina Gasparetto, MD, Sundar Jagannath, Robert M. Rifkin, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne I. Wagner, PhD, James L. Omel, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 3129.

https://doi.org/10.1182/blood-2019-126205

Published: 2019

Journal Articles

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

Ethan G. Thompson, PhD, Yue Jiang, PhD, Timothy B. Campbell, MD PhD, Jaymes Fuller, PhD, Shari Kaiser, PhD, Afshin Mashadi-Hossein, MSc, Julie Rytlewski, PhD, Nathan Martin, PhD, Olivia Finney, PhD, Katja Kleinsteuber, PhD, Eric Alonzo, PhD, Chetanya Pandya, PhD, Amit Agarwal, MD PhD, Kristen Hege, Noopur S. Raje, MD, Nikhil C. Munshi, MD, Ronald J. Hause, PhD

Blood (2019) 134 (Supplement_1): 4328.

https://doi.org/10.1182/blood-2019-124998

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma

Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect ® MM Registry

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only